# US 2021/0239704 A1 · Analogs and conjugates of beta-aminoisobutyric acid (baib)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0239704 A1
- Document ID: US20210239704A1
- Status: Published application
- Kind: A1
- Application number: 17/188,710
- Filed: 2021-03-01
- Published: 2021-08-05
- Earliest claimed: 2015-04-30
- Assignees: IDEXX Laboratories, Inc.
- Applicants: Idexx Laboratories, Inc.
- Inventors: Mahalakshmi Yerramilli; Edward Obare; John Joseph Quinn; Murthy VSN Yerramilli
- Web page: https://patentgrep.com/patent/US20210239704A1

## CPC

- G01N 33/6812: {Assays for specific amino acids}
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- C07D 207/448: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/6806: {Determination of free amino acids}
- C07C 229/12: to carbon atoms of acyclic carbon skeletons
- C07C 271/22: to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C07C 323/22: containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07D 207/456: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- G01N 2800/347: Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Analogs and conjugates of β-Aminoisobutyric Acid (BAIB).

## Claims

### Claim 1

A compound having the structural formula:
or a salt thereof, and/or solvate or hydrate thereof, wherein:
A is —OH and B is —C(O)R1;
A is —NR2R3 and B is H;
A is —OH and B is fluorenylmethyloxycarbonyl;
A is —OH and B is —(C5-alkyl)-NR4R5; or
A is
and B is H;
wherein
R1 is —(C1-C2-alkyl)-SR6;
R2 and R4 are H;
R3 is —(C1-C2-alkyl)-SR7;
R5 is —(C3-alkyl)-C(O)OH;
wherein
R6 is H or
R7 is H, —(C1-alkyl)-C(O)NHR9, or
wherein
R8 and R10 are a —(C1-alkyl)-D
R9 is a —(C4-alkyl)-E; and
wherein
D and E are a label or a protein.

### Claim 2 (depends on 1)

The compound of claim 1, wherein D and E are labels selected from the group consisting of a radioisotope label, a chemiluminescent dye, an electrochemical label, a metal chelate, a latex particle, a fluorescent label, a horseradish peroxidase, alkaline phosphatase, biotin, avidin, streptavidin, digioxigenin, maltose, oligohistidine, 2,4-dintirobenzene, phenylarsenate, ssDNA, dsDNA, bovine serum albumin, keyhole limpet hemocyanin, and glucose-6-phosphate dehydrogenase.

### Claim 3 (depends on 1)

The compound of claim 1, wherein D and E are proteins selected form the group consisting of bovine serum albumin, keyhole limpet hemocyanin, glucose-6-phosphate dehydrogenase, avidin, streptavidin, and oligohistidine.

### Claim 4 (depends on 1)

The compound of claim 1, where D is a protein selected from bovine serum albumin or keyhole limpet hemocyanin.

### Claim 5 (depends on 1)

The compound of claim 1, wherein E is a protein glucose-6-phosphate dehydrogenase.

### Claim 6 (depends on 1)

The compound of claim 1, wherein A is —OH and B is —C(O)R1, R1 is a —(C1 alkyl)-SR6, and R6 is H.

### Claim 7 (depends on 1)

The compound of claim 1, wherein A is —OH and B is —C(O)R1, R1 is —(C1 alkyl)-SR6, R6 is
R8 is —(C1-alkyl)-D, and D is KLH.

### Claim 8 (depends on 1)

The compound of claim 1, wherein A is —OH and B is —C(O)R1, R1 is a —(C1 alkyl)-SR6, R6 is
R8 is —(C1 alkyl)-D, and D is BSA.

### Claim 9 (depends on 1)

The compound of claim 1, wherein A is a —NR2R3 and B is H, R2 is H, R3 is a —(C2-alkyl)-SR7, and R7 is H.

### Claim 10 (depends on 1)

The compound of claim 1, wherein A is —NR2R3 and B is H, R2 is H, R3 is —(C2 alkyl)-SR7, R7 is
R10 is —(C1 alkyl)-D, and D is KLH.

### Claim 11 (depends on 1)

The compound of claim 1, wherein A is —NR2R3 and B is H, R2 is H, R3 is —(C2 alkyl)-SR7, R7 is
R10 is —(C1 alkyl)-D, and D is BSA.

### Claim 12 (depends on 1)

The compound of claim 1, wherein A is —NR2R3 and B is H, R2 is H, R3 is —(C2 alkyl)-SR7, R7 is —(C1 alkyl)C(O)NHR9, R9 is —(C4 alkyl)-E, and E is G6PDH.

### Claim 13 (depends on 1)

The compound of claim 1, wherein A is —OH and B is fluorenylmethyloxycarbonyl.

### Claim 14 (depends on 1)

The compound of claim 1, wherein A is —OH and B is —(C5-alkyl)-NR4R5, R4 is H, and R5 is a —(C3-alkyl)-C(O)OH.

### Claim 15 (depends on 11)

The compound of claim 11, wherein R5 has the structural formula:

### Claim 16 (depends on 1)

The compound of claim 1, wherein A is
and B is H.

### Claim 17 (depends on 1)

The compound of claim 1 having the formula:

### Claim 18 (depends on 1)

The compound of claim 1 having the formula:

### Claim 19 (depends on 1)

The compound of claim 1 having the formula:

### Claim 20 (depends on 1)

The compound of claim 1 having the formula:

### Claim 21 (depends on 1)

The compound of claim 1 having the formula:

### Claim 22 (depends on 1)

The compound of claim 1 having the formula:

### Claim 23 (depends on 1)

The compound of claim 1 having the formula:

### Claim 24 (depends on 1)

The compound of claim 1 having the formula:

### Claim 25 (depends on 1)

The compound of claim 1 having the formula:

### Claim 26 (depends on 1)

The compound of claim 1 having the formula:
